Arcus Biosciences, Inc. (RCUS)
29.21
-1.38
(-4.51%)
USD |
NYSE |
Aug 28, 16:00
29.18
-0.03
(-0.10%)
Pre-Market: 20:00
Arcus Biosciences Cash from Operations (Quarterly) : -119.00M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -119.00M |
| March 31, 2026 | -138.00M |
| December 31, 2025 | -120.00M |
| September 30, 2025 | -97.00M |
| June 30, 2025 | -133.00M |
| March 31, 2025 | -132.00M |
| December 31, 2024 | -100.00M |
| September 30, 2024 | 26.00M |
| June 30, 2024 | -94.00M |
| March 31, 2024 | -2.00M |
| December 31, 2023 | -88.00M |
| September 30, 2023 | -63.00M |
| June 30, 2023 | -57.00M |
| March 31, 2023 | -98.00M |
| December 31, 2022 | -69.74M |
| September 30, 2022 | -80.96M |
| June 30, 2022 | -65.30M |
| March 31, 2022 | 654.00M |
| Date | Value |
|---|---|
| December 31, 2021 | -62.10M |
| September 30, 2021 | -53.76M |
| June 30, 2021 | -74.00M |
| March 31, 2021 | -66.32M |
| December 31, 2020 | -49.88M |
| September 30, 2020 | 216.26M |
| June 30, 2020 | -23.94M |
| March 31, 2020 | -31.28M |
| December 31, 2019 | -9.471M |
| September 30, 2019 | -27.40M |
| June 30, 2019 | -19.75M |
| March 31, 2019 | -16.84M |
| December 31, 2018 | -7.107M |
| September 30, 2018 | -11.76M |
| June 30, 2018 | -10.88M |
| March 31, 2018 | -13.25M |
| December 31, 2017 | -25.06M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 240.89M |
| AVITA Medical, Inc. | -3.630M |
| Iovance Biotherapeutics, Inc. | -60.84M |
| Editas Medicine, Inc. | -29.57M |
| Recursion Pharmaceuticals, Inc. | -105.95M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 52.00M |
| Cash from Financing (Quarterly) | 16.00M |
| Free Cash Flow | -475.00M |
| Free Cash Flow Per Share (Quarterly) | -0.9437 |
| Free Cash Flow to Equity (Quarterly) | -120.00M |
| Free Cash Flow to Firm (Quarterly) | -116.00M |
| Free Cash Flow Yield | -13.65% |